Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Sep. 30, 2013 | Oct. 25, 2013 | |
Document And Entity Information | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Document Fiscal Year Focus | '2013 | ' |
Entity Registrant Name | 'KIMBERLY CLARK CORP | ' |
Entity Central Index Key | '0000055785 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Large Accelerated Filer | ' |
Entity Common Stock, Shares Outstanding | ' | 381,638,993 |
Consolidated_Income_Statement
Consolidated Income Statement (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Income Statement [Abstract] | ' | ' | ' | ' |
Net Sales | $5,262 | $5,246 | $15,847 | $15,756 |
Cost of products sold | 3,457 | 3,480 | 10,420 | 10,531 |
Gross Profit | 1,805 | 1,766 | 5,427 | 5,225 |
Marketing, research and general expenses | 990 | 988 | 3,029 | 3,003 |
Other (income) and expense, net | 8 | -5 | 12 | -15 |
Operating Profit | 807 | 783 | 2,386 | 2,237 |
Interest income | 6 | 4 | 16 | 13 |
Interest expense | -73 | -70 | -211 | -212 |
Income Before Income Taxes and Equity Interests | 740 | 717 | 2,191 | 2,038 |
Provision for income taxes | -224 | -223 | -685 | -621 |
Income Before Equity Interests | 516 | 494 | 1,506 | 1,417 |
Share of net income of equity companies | 49 | 43 | 157 | 125 |
Net Income | 565 | 537 | 1,663 | 1,542 |
Net income attributable to noncontrolling interests | -19 | -20 | -60 | -59 |
Net Income Attributable to Kimberly-Clark Corporation | $546 | $517 | $1,603 | $1,483 |
Net Income Attributable to Kimberly-Clark Corporation | ' | ' | ' | ' |
Basic | $1.43 | $1.31 | $4.16 | $3.77 |
Diluted | $1.42 | $1.30 | $4.13 | $3.73 |
Cash Dividends Declared | $0.81 | $0.74 | $2.43 | $2.22 |
Consolidated_Statement_Of_Comp
Consolidated Statement Of Comprehensive Income (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Statement of Other Comprehensive Income [Abstract] | ' | ' | ' | ' |
Net Income | $565 | $537 | $1,663 | $1,542 |
Other Comprehensive Income, Net of Tax | ' | ' | ' | ' |
Unrealized currency translation adjustments | 204 | 141 | -387 | 133 |
Employee postretirement benefits | -5 | -54 | 84 | -46 |
Other | -19 | -10 | 9 | -10 |
Total Other Comprehensive Income, Net of Tax | 180 | 77 | -294 | 77 |
Comprehensive Income | 745 | 614 | 1,369 | 1,619 |
Comprehensive income attributable to noncontrolling interests | -32 | -27 | -59 | -70 |
Comprehensive Income Attributable to Kimberly-Clark Corporation | $713 | $587 | $1,310 | $1,549 |
Consolidated_Balance_Sheet
Consolidated Balance Sheet (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Current Assets | ' | ' |
Cash and cash equivalents | $1,179 | $1,106 |
Accounts receivable, net | 2,502 | 2,642 |
Note receivable | 396 | 0 |
Inventories | 2,245 | 2,348 |
Other current assets | 572 | 493 |
Total Current Assets | 6,894 | 6,589 |
Property, Plant and Equipment, Net | 7,871 | 8,095 |
Investments in Equity Companies | 429 | 355 |
Goodwill | 3,223 | 3,337 |
Other Intangible Assets | 257 | 246 |
Long-Term Note Receivable | 0 | 395 |
Other Assets | 690 | 856 |
TOTAL ASSETS | 19,364 | 19,873 |
Current Liabilities | ' | ' |
Debt payable within one year | 1,087 | 1,115 |
Trade accounts payable | 2,360 | 2,443 |
Accrued expenses | 2,023 | 2,244 |
Dividends payable | 310 | 289 |
Total Current Liabilities | 5,780 | 6,091 |
Long-Term Debt | 5,388 | 5,070 |
Noncurrent Employee Benefits | 1,725 | 1,992 |
Other Liabilities | 946 | 884 |
Redeemable Preferred and Common Securities of Subsidiaries | 549 | 549 |
Stockholders' Equity | ' | ' |
Kimberly-Clark Corporation | 4,667 | 4,985 |
Noncontrolling interests | 309 | 302 |
Total Stockholders' Equity | 4,976 | 5,287 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $19,364 | $19,873 |
Consolidated_Cash_Flow_Stateme
Consolidated Cash Flow Statement (USD $) | 9 Months Ended | |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Operating Activities | ' | ' |
Net Income | $1,663 | $1,542 |
Depreciation and amortization | 641 | 642 |
Asset impairments | 42 | 0 |
Stock-based compensation | 73 | 57 |
Deferred income taxes | 128 | 320 |
Net (gains) losses on asset dispositions | 0 | 15 |
Equity companies' earnings in excess of dividends paid | -75 | -53 |
(Increase) decrease in operating working capital | -259 | -335 |
Postretirement benefits | -135 | -11 |
Other | 17 | -8 |
Cash Provided by Operations | 2,095 | 2,169 |
Investing Activities | ' | ' |
Capital spending | -697 | -763 |
Acquisitions of businesses | -32 | -5 |
Proceeds from dispositions of property | 113 | 6 |
Proceeds from sales of investments | 16 | 14 |
Investments in time deposits | -46 | -61 |
Maturities of time deposits | 66 | 78 |
Other | -10 | 2 |
Cash Used for Investing | -590 | -729 |
Financing Activities | ' | ' |
Cash dividends paid | -913 | -859 |
Change in short-term borrowings | 22 | 464 |
Debt proceeds | 889 | 315 |
Debt repayments | -542 | -471 |
Cash paid on redeemable preferred securities of subsidiary | -21 | -21 |
Proceeds from exercise of stock options | 164 | 523 |
Acquisitions of common stock for the treasury | -959 | -962 |
Other | 7 | 25 |
Cash Used for Financing | -1,353 | -986 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -79 | 31 |
Increase (Decrease) in Cash and Cash Equivalents | 73 | 485 |
Cash and Cash Equivalents - Beginning of Year | 1,106 | 764 |
Cash and Cash Equivalents - End of Period | $1,179 | $1,249 |
Accounting_Policies
Accounting Policies | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Accounting Policies | ' |
Accounting Policies | |
Basis of Presentation | |
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. | |
For further information, refer to the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2012. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries. | |
Annual Goodwill Impairment Test | |
Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. During the third quarter of 2013, we changed the measurement date of our annual goodwill impairment test from the beginning of the fourth quarter to the beginning of the third quarter. This change did not result in the delay, acceleration or avoidance of an impairment charge. We believe this timing is preferable as it better aligns the goodwill impairment test with our strategic business planning process, which is a key component of the goodwill impairment test. The change was applied prospectively, as retrospective application would have been impractical because we are unable to objectively select assumptions that would have been used in previous periods without the benefit of hindsight. We have completed the required annual testing of goodwill for impairment for all reporting units and have determined that goodwill is not impaired. | |
Highly Inflationary Accounting for Venezuelan Operations | |
We account for our operations in Venezuela using highly inflationary accounting. On February 13, 2013, the Venezuelan government announced a devaluation of the Central Bank of Venezuela ("Central Bank") regulated currency exchange system rate to 6.3 bolivars per U.S. dollar and the elimination of the SITME rate. As a result of the devaluation, we recorded a $26 after tax charge ($36 pre-tax) related to the remeasurement of the local currency-denominated balance sheet to the new exchange rate in the quarter ended March 31, 2013. Prior to devaluation, we used the Central Bank SITME rate of 5.4 bolivars per U.S. dollar to measure K-C Venezuela's bolivar-denominated transactions into U.S. dollars. The $36 pre-tax charge is reflected in the Consolidated Income Statement in other (income) and expense, net for the nine months ended September 30, 2013. In the Consolidated Cash Flow Statement, this non-cash charge is included in other in cash provided by operations. | |
At September 30, 2013, K-C Venezuela had a bolivar-denominated net monetary asset position of $285 and our net investment in K-C Venezuela was $414, both valued at 6.3 bolivars per U.S. dollar. Net sales of K-C Venezuela represented approximately 2 percent of consolidated net sales for the three and nine month periods ended September 30, 2013 and 2012. |
European_Strategic_Changes
European Strategic Changes (European Strategic Changes [Member]) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
European Strategic Changes [Member] | ' | |||||||
Restructuring Cost and Reserve | ' | |||||||
European Strategic Changes | ' | |||||||
European Strategic Changes | ||||||||
In October 2012, we approved strategic changes related to our Western and Central European consumer and professional businesses to focus our resources and investments on stronger market positions and growth opportunities. We have exited the diaper category in that region, with the exception of the Italian market, and divested or exited some lower-margin businesses, mostly in consumer tissue, in certain markets. The changes primarily affect our consumer businesses, with a modest impact on K-C Professional ("KCP"). The restructuring actions commenced in the fourth quarter of 2012 and are expected to be completed by December 31, 2014. Restructuring actions related to the strategic changes involve the sale or closure of five of our European manufacturing facilities and streamlining our administrative organization. | ||||||||
The following charges were incurred in connection with the European strategic changes: | ||||||||
Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2013 | |||||||
Asset impairments | $ | 22 | $ | 22 | ||||
Charges for workforce reductions | (23 | ) | 4 | |||||
Asset write-offs | 1 | 13 | ||||||
Incremental depreciation | 3 | 18 | ||||||
Benefit from pension curtailment | (1 | ) | (30 | ) | ||||
Other exit costs | 4 | 17 | ||||||
Cost of products sold | 6 | 44 | ||||||
Charges for workforce reductions and other included in marketing, research and general expenses and other (income) and expense, net | 8 | 23 | ||||||
Provision for income taxes | (4 | ) | (15 | ) | ||||
Net charges | $ | 10 | $ | 52 | ||||
See Note 9 for the charges by segment. | ||||||||
Through September 30, 2013, cumulative pre-tax charges for the strategic changes were $366 ($294 after tax), including cumulative pre-tax cash charges of $187. Cumulative pre-tax charges by segment were as follows: Personal Care - $243, Consumer Tissue - $88 and K-C Professional - $32. | ||||||||
The following summarizes the cash charges recorded and reconciles these charges to accrued expenses: | ||||||||
2013 | ||||||||
Accrued expenses - January 1 | $ | 133 | ||||||
Charges for workforce reductions and other costs | 53 | |||||||
Cash payments | (132 | ) | ||||||
Currency and other | (9 | ) | ||||||
Accrued expenses - September 30 | $ | 45 | ||||||
Pulp_And_Tissue_Restructuring
Pulp And Tissue Restructuring (Pulp And Tissue Restructuring [Member]) | 9 Months Ended |
Sep. 30, 2013 | |
Pulp And Tissue Restructuring [Member] | ' |
Restructuring Cost and Reserve | ' |
Pulp and Tissue Restructuring | ' |
Pulp and Tissue Restructuring Actions | |
In 2011 and 2012, we executed pulp and tissue restructuring actions in order to exit our remaining integrated pulp manufacturing operations and improve the underlying profitability and return on invested capital of our consumer tissue and KCP businesses. These actions involved the streamlining, sale or closure of seven of our manufacturing facilities around the world. In conjunction with these actions, we exited certain non-strategic products, primarily non-branded offerings, and transferred some production to lower-cost facilities in order to improve overall profitability and returns. The actions were substantially complete at December 31, 2012. | |
During the three months ended September 30, 2012, charges of $30 and $1 were recorded in cost of products sold and marketing, research and general expenses, respectively, for the restructuring actions. A related benefit of $15 was recorded in provision for income taxes. On a geographic basis, charges of $10 and $22 and a credit of $1 were recorded in the United States, Australia and other countries, respectively. | |
During the nine months ended September 30, 2012, charges of $83 and $2 were recorded in cost of products sold and marketing, research and general expenses, respectively, for the restructuring actions. A related benefit of $29 was recorded in provision for income taxes. On a geographic basis, $58 and $27 of the charges were recorded in the United States and Australia, respectively. | |
See Note 9 for the charges by segment. |
Fair_Value_Information
Fair Value Information | 9 Months Ended | |||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||||||
Fair Value Information | ' | |||||||||||||||||
Fair Value Information | ||||||||||||||||||
The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are: | ||||||||||||||||||
Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities. | ||||||||||||||||||
Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly. | ||||||||||||||||||
Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable. | ||||||||||||||||||
A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. | ||||||||||||||||||
During the nine months ended September 30, 2013 and for the full year 2012, there were no significant transfers among level 1, 2, or 3 fair value determinations. | ||||||||||||||||||
Set forth below are the assets and liabilities that are measured on a recurring basis at fair value and the inputs used to develop those fair value measurements. | ||||||||||||||||||
September 30, 2013 | Fair Value Measurements | |||||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||||
Assets | ||||||||||||||||||
Company-owned life insurance (“COLI”) | $ | 53 | $ | — | $ | 53 | $ | — | ||||||||||
Available-for-sale securities | 20 | 20 | — | — | ||||||||||||||
Derivatives | 69 | — | 69 | — | ||||||||||||||
Total | $ | 142 | $ | 20 | $ | 122 | $ | — | ||||||||||
Liabilities | ||||||||||||||||||
Derivatives | $ | 57 | $ | — | $ | 57 | $ | — | ||||||||||
December 31, 2012 | Fair Value Measurements | |||||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||||
Assets | ||||||||||||||||||
COLI | $ | 49 | $ | — | $ | 49 | $ | — | ||||||||||
Available-for-sale securities | 17 | 17 | — | — | ||||||||||||||
Derivatives | 61 | — | 61 | — | ||||||||||||||
Total | $ | 127 | $ | 17 | $ | 110 | $ | — | ||||||||||
Liabilities | ||||||||||||||||||
Derivatives | $ | 63 | $ | — | $ | 63 | $ | — | ||||||||||
The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in other assets. Available-for-sale securities are included in other assets. See Note 8 for information on the classification of derivatives in the Consolidated Balance Sheet. | ||||||||||||||||||
Level 1 Fair Values - The fair values of certain available-for-sale securities are based on quoted market prices in active markets for identical assets. | ||||||||||||||||||
Level 2 Fair Values - The fair value of the COLI policies is derived from investments in a mix of money market, fixed income and equity funds managed by unrelated fund managers. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on LIBOR rates and interest rate swap curves and NYMEX price quotations, respectively. The fair value of hedging instruments used to manage foreign currency risk is based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Additional information on our use of derivative instruments is contained in Note 8. | ||||||||||||||||||
The following table includes the fair value of our financial instruments for which disclosure of fair value is required: | ||||||||||||||||||
Fair Value Hierarchy Level | Carrying Amount | Estimated Fair Value | Carrying Amount | Estimated Fair Value | ||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||||
Assets | ||||||||||||||||||
Cash and cash equivalents(a) | 1 | $ | 1,179 | $ | 1,179 | $ | 1,106 | $ | 1,106 | |||||||||
Time deposits(b) | 1 | 202 | 202 | 224 | 224 | |||||||||||||
Note receivable(c) | 3 | 396 | 397 | 395 | 392 | |||||||||||||
Liabilities and redeemable securities of subsidiaries | ||||||||||||||||||
Short-term debt(d) | 2 | 374 | 374 | 359 | 359 | |||||||||||||
Monetization loan(c) | 3 | 397 | 398 | 397 | 400 | |||||||||||||
Long-term debt(e) | 2 | 5,704 | 6,361 | 5,429 | 6,527 | |||||||||||||
Redeemable preferred securities of subsidiary(c) | 3 | 506 | 532 | 506 | 543 | |||||||||||||
Redeemable common securities of subsidiary(f) | 3 | 43 | 43 | 43 | 43 | |||||||||||||
(a) | Cash equivalents are comprised of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. | |||||||||||||||||
(b) | Time deposits are comprised of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value. | |||||||||||||||||
(c) | The note, monetization loan and redeemable preferred securities of subsidiary are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest payment dates. | |||||||||||||||||
(d) | Short-term debt is comprised of U.S. commercial paper and other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. | |||||||||||||||||
(e) | Long-term debt includes the current portion of these debt instruments and excludes the monetization loan. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly. | |||||||||||||||||
(f) | The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions. |
Employee_Postretirement_Benefi
Employee Postretirement Benefits | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract] | ' | |||||||||||||||
Employee Postretirement Benefits | ' | |||||||||||||||
Employee Postretirement Benefits | ||||||||||||||||
The table below presents net periodic benefit cost information for defined benefit plans and other postretirement benefit plans: | ||||||||||||||||
Pension Benefits | Other Benefits | |||||||||||||||
Three Months Ended September 30 | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Service cost | $ | 13 | $ | 10 | $ | 4 | $ | 3 | ||||||||
Interest cost | 63 | 69 | 9 | 9 | ||||||||||||
Expected return on plan assets | (82 | ) | (82 | ) | — | — | ||||||||||
Recognized net actuarial loss | 28 | 27 | 2 | — | ||||||||||||
Curtailment (see Note 2) | (1 | ) | — | — | — | |||||||||||
Other | 2 | 3 | — | 1 | ||||||||||||
Net periodic benefit cost | $ | 23 | $ | 27 | $ | 15 | $ | 13 | ||||||||
Pension Benefits | Other Benefits | |||||||||||||||
Nine Months Ended September 30 | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Service cost | $ | 40 | $ | 34 | $ | 12 | $ | 11 | ||||||||
Interest cost | 191 | 209 | 25 | 28 | ||||||||||||
Expected return on plan assets | (246 | ) | (247 | ) | — | — | ||||||||||
Recognized net actuarial loss | 91 | 82 | 2 | — | ||||||||||||
Curtailment (see Note 2) | (30 | ) | — | — | — | |||||||||||
Other | (1 | ) | 20 | — | — | |||||||||||
Net periodic benefit cost | $ | 45 | $ | 98 | $ | 39 | $ | 39 | ||||||||
For the nine months ended September 30, 2013 and 2012, we made cash contributions of $175 and $95, respectively, to our pension trusts. We expect to contribute approximately $200 to our defined benefit pension plans for the full year 2013. |
Earnings_Per_Share
Earnings Per Share | 9 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Earnings Per Share [Abstract] | ' | ||||||||||||
Earnings Per Share | ' | ||||||||||||
Earnings Per Share ("EPS") | |||||||||||||
There are no adjustments required to be made to net income for purposes of computing basic and diluted EPS. The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows: | |||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||
30-Sep | 30-Sep | ||||||||||||
(Millions of shares) | 2013 | 2012 | 2013 | 2012 | |||||||||
Basic | 382.8 | 393.9 | 384.9 | 393.8 | |||||||||
Dilutive effect of stock options | 1.4 | 1.7 | 1.6 | 1.9 | |||||||||
Dilutive effect of restricted share and restricted share unit awards | 1.6 | 1.1 | 1.5 | 1.4 | |||||||||
Diluted | 385.8 | 396.7 | 388 | 397.1 | |||||||||
Outstanding options during the three and nine month periods ended September 30, 2013 of 1.8 million and 0.9 million, respectively, were not included in the computation of diluted EPS mainly because the exercise prices of the options were greater than the average market price of the common shares during the periods. There were no significant outstanding options excluded from the computation of diluted EPS during the three and nine month periods ended September 30, 2012. | |||||||||||||
The number of common shares outstanding as of September 30, 2013 and 2012 was 382.1 million and 392.3 million, respectively. |
Stockholders_Equity
Stockholders' Equity | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Equity [Abstract] | ' | ||||||||||||||||
Stockholders' Equity | ' | ||||||||||||||||
Stockholders' Equity | |||||||||||||||||
Set forth below is a reconciliation for the nine months ended September 30, 2013 of the carrying amount of total stockholders' equity from the beginning of the period to the end of the period. In addition, the reconciliation displays the amount of net income allocable to redeemable securities of subsidiaries. | |||||||||||||||||
Stockholders' Equity Attributable to | |||||||||||||||||
Comprehensive Income | The Corporation | Noncontrolling Interests | Redeemable Securities of Subsidiaries | ||||||||||||||
Balance at December 31, 2012 | $ | 4,985 | $ | 302 | $ | 549 | |||||||||||
Comprehensive Income | |||||||||||||||||
Net Income | $ | 1,663 | 1,603 | 37 | 23 | ||||||||||||
Other comprehensive income, net of tax | |||||||||||||||||
Unrealized translation | (387 | ) | (386 | ) | (1 | ) | — | ||||||||||
Employee postretirement benefits | 84 | 84 | — | — | |||||||||||||
Other | 9 | 9 | — | — | |||||||||||||
Total Comprehensive Income | $ | 1,369 | |||||||||||||||
Stock-based awards exercised or vested | 163 | — | — | ||||||||||||||
Recognition of stock-based compensation | 73 | — | — | ||||||||||||||
Income tax benefits on stock-based compensation | 30 | — | — | ||||||||||||||
Shares repurchased | (963 | ) | — | — | |||||||||||||
Dividends declared | (934 | ) | (27 | ) | — | ||||||||||||
Other | 3 | (1 | ) | (2 | ) | ||||||||||||
Return of redeemable securities of subsidiaries | — | (1 | ) | (21 | ) | ||||||||||||
Balance at September 30, 2013 | $ | 4,667 | $ | 309 | $ | 549 | |||||||||||
In the nine months ended September 30, 2013, we repurchased 10.0 million shares at a total cost of $950. | |||||||||||||||||
Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in Accumulated Other Comprehensive Income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation is recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation. | |||||||||||||||||
Also included in unrealized translation are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments. | |||||||||||||||||
The change in net unrealized currency translation for the nine months ended September 30, 2013 was primarily due to a strengthening of the U.S. dollar against the Australian dollar, as well as most other foreign currencies. | |||||||||||||||||
The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows: | |||||||||||||||||
Unrealized Translation | Defined Benefit Pension Plans | Other Postretirement Benefit Plans | Cash Flow Hedges and Other | ||||||||||||||
Balance as of December 31, 2011 | $ | (221 | ) | $ | (1,578 | ) | $ | (31 | ) | $ | (36 | ) | |||||
Other comprehensive income/(loss) before reclassifications | 124 | (101 | ) | (9 | ) | (10 | ) | ||||||||||
(Income)/loss reclassified from AOCI | — | 62 | (a) | — | (a) | — | |||||||||||
Net current period other comprehensive income/(loss) | 124 | (39 | ) | (9 | ) | (10 | ) | ||||||||||
Balance as of September 30, 2012 | $ | (97 | ) | $ | (1,617 | ) | $ | (40 | ) | $ | (46 | ) | |||||
Balance as of December 31, 2012 | $ | (26 | ) | $ | (1,928 | ) | $ | (53 | ) | $ | (52 | ) | |||||
Other comprehensive income/(loss) before reclassifications | (386 | ) | 57 | 1 | 17 | ||||||||||||
(Income)/loss reclassified from AOCI | — | 28 | (a) | (2 | ) | (a) | (8 | ) | |||||||||
Net current period other comprehensive income/(loss) | (386 | ) | 85 | (1 | ) | 9 | |||||||||||
Balance as of September 30, 2013 | $ | (412 | ) | $ | (1,843 | ) | $ | (54 | ) | $ | (43 | ) | |||||
(a) | Included in computation of net periodic pension and postretirement benefits costs (see Note 5). |
Objectives_And_Strategies_For_
Objectives And Strategies For Using Derivatives | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | |||||||||||||||
Objectives And Strategies For Using Derivatives | ' | |||||||||||||||
Objectives and Strategies for Using Derivatives | ||||||||||||||||
As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments. We enter into derivative instruments to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of pulp, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated and qualify as cash flow hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments. Interest rate risk is managed using a portfolio of variable- and fixed-rate debt composed of short- and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable- and fixed-rate debt and are designated and qualify as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, using forward-starting swaps or treasury locks, and these contracts are designated as cash flow hedges. We use derivative instruments, such as forward swap contracts, to hedge a limited portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months. Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowing. Translation exposure, which results from changes in translation rates between functional currencies and the U.S. dollar, generally is not hedged. However, consistent with other years, a portion of our net investment in our Mexican affiliate has been hedged. At September 30, 2013, we had in place net investment hedges of $73 for a portion of our investment in our Mexican affiliate. | ||||||||||||||||
Set forth below is a summary of the total designated and undesignated fair values of our derivative instruments: | ||||||||||||||||
Assets | Liabilities | |||||||||||||||
September 30, | December 31, | September 30, | December 31, | |||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Foreign currency exchange contracts | $ | 52 | $ | 52 | $ | 55 | $ | 17 | ||||||||
Interest rate contracts | 16 | 7 | 1 | 43 | ||||||||||||
Commodity price contracts | 1 | 2 | 1 | 3 | ||||||||||||
Total | $ | 69 | $ | 61 | $ | 57 | $ | 63 | ||||||||
The derivative assets are included in the Consolidated Balance Sheet in other current assets and other assets, as appropriate. The derivative liabilities are included in the Consolidated Balance Sheet in accrued expenses and other liabilities, as appropriate. | ||||||||||||||||
Effect of Derivative Instruments on Results of Operations and Other Comprehensive Income | ||||||||||||||||
Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in current earnings. The offset to the change in fair values of the related hedged items also is recorded in current earnings. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to interest expense over the life of the related debt. At September 30, 2013, the aggregate notional values of outstanding interest rate contracts designated as fair value hedges were $250. Fair value hedges resulted in no significant ineffectiveness in the nine months ended September 30, 2013 and 2012. For the nine month periods ended September 30, 2013 and 2012, gains or losses recognized in interest expense for interest rate swaps were not significant. For the nine month periods ended September 30, 2013 and 2012, no gain or loss was recognized in earnings as a result of a hedged firm commitment no longer qualifying as a fair value hedge. | ||||||||||||||||
For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same period that the hedged exposure affects earnings. As of September 30, 2013, outstanding commodity forward contracts were in place to hedge a limited portion of our estimated requirements of the related underlying commodities in the remainder of 2013 and future periods. As of September 30, 2013, the aggregate notional values of outstanding foreign exchange and interest rate derivative contracts designated as cash flow hedges were $1 billion and $200, respectively. Cash flow hedges resulted in no significant ineffectiveness for the nine months ended September 30, 2013 and 2012. For the nine months ended September 30, 2013 and 2012, no gains or losses were reclassified into earnings as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At September 30, 2013, amounts to be reclassified from AOCI during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at September 30, 2013 is October 2015. | ||||||||||||||||
Undesignated foreign exchange hedging instrument gains or losses are immediately recognized in other (income) and expense, net. Gains of $77 and $30 were recorded in the three month periods ended September 30, 2013 and 2012, respectively. Losses of $65 and gains of $31 were recorded in the nine month periods ended September 30, 2013 and 2012, respectively. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At September 30, 2013, the notional amount of these undesignated derivative instruments was $2.6 billion. |
Description_Of_Business_Segmen
Description Of Business Segments | 9 Months Ended | ||||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||||
Description of Business Segments | ' | ||||||||||||||||||||||
Description Of Business Segments | ' | ||||||||||||||||||||||
Description of Business Segments | |||||||||||||||||||||||
We are organized into operating segments based on product groupings. These operating segments have been aggregated into four reportable global business segments: Personal Care, Consumer Tissue, KCP and Health Care. The reportable segments were determined in accordance with how our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes other (income) and expense, net and income and expense not associated with the business segments, including the charges related to the European strategic changes and the pulp and tissue restructuring actions described in Notes 2 and 3, respectively. | |||||||||||||||||||||||
The principal sources of revenue in each global business segment are described below: | |||||||||||||||||||||||
• | Personal Care brands offer parents a trusted partner in caring for their families and deliver confidence, protection and discretion to adults through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, Kotex, Depend, Plenitud, Poise and other brand names. | ||||||||||||||||||||||
• | Consumer Tissue offers a wide variety of innovative solutions and trusted brands that touch and improve people's lives every day. Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Hakle, Page and other brand names. | ||||||||||||||||||||||
• | K‑C Professional helps transform workplaces for employees and patrons, making them healthier, safer and more productive, through a range of solutions and supporting products such as apparel, wipers, soaps, sanitizers, tissues and towels. Key brands in this segment include Kleenex, Scott, WypAll, Kimtech and Jackson Safety. | ||||||||||||||||||||||
• | Health Care provides essentials that help restore patients to better health and improve the quality of patients' lives. This segment offers surgical and infection prevention products for the operating room, and a portfolio of innovative medical devices focused on pain management, respiratory and digestive health. This business is a global leader in education to prevent healthcare-associated infections. Products are sold primarily under the Kimberly-Clark and ON-Q brand names. | ||||||||||||||||||||||
The following schedules present information concerning consolidated operations by business segment: | |||||||||||||||||||||||
Three Months Ended September 30 | Nine Months Ended September 30 | ||||||||||||||||||||||
2013 | 2012 | Change | 2013 | 2012 | Change | ||||||||||||||||||
NET SALES | |||||||||||||||||||||||
Personal Care | $ | 2,383 | $ | 2,414 | -1.3 | % | $ | 7,170 | $ | 7,196 | -0.4 | % | |||||||||||
Consumer Tissue | 1,626 | 1,605 | 1.3 | % | 4,969 | 4,852 | 2.4 | % | |||||||||||||||
K-C Professional | 843 | 822 | 2.6 | % | 2,477 | 2,458 | 0.8 | % | |||||||||||||||
Health Care | 403 | 396 | 1.8 | % | 1,201 | 1,212 | -0.9 | % | |||||||||||||||
Corporate & Other | 7 | 9 | N.M. | 30 | 38 | N.M. | |||||||||||||||||
TOTAL NET SALES | $ | 5,262 | $ | 5,246 | 0.3 | % | $ | 15,847 | $ | 15,756 | 0.6 | % | |||||||||||
OPERATING PROFIT | |||||||||||||||||||||||
Personal Care | $ | 427 | $ | 436 | -2.1 | % | $ | 1,300 | $ | 1,241 | 4.8 | % | |||||||||||
Consumer Tissue | 233 | 216 | 7.9 | % | 713 | 652 | 9.4 | % | |||||||||||||||
K-C Professional | 155 | 144 | 7.6 | % | 459 | 407 | 12.8 | % | |||||||||||||||
Health Care | 70 | 59 | 18.6 | % | 168 | 168 | — | ||||||||||||||||
Corporate & Other(a) | (70 | ) | (77 | ) | N.M. | (242 | ) | (246 | ) | N.M. | |||||||||||||
Other (income) and expense, net | 8 | (5 | ) | N.M. | 12 | (15 | ) | N.M. | |||||||||||||||
TOTAL OPERATING PROFIT | $ | 807 | $ | 783 | 3.1 | % | $ | 2,386 | $ | 2,237 | 6.7 | % | |||||||||||
N.M. - Not meaningful | |||||||||||||||||||||||
(a) | Corporate & Other includes the following charges: | ||||||||||||||||||||||
European Strategic Changes | Pulp & Tissue Restructuring Actions | ||||||||||||||||||||||
Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2013 | Three Months Ended September 30, 2012 | Nine Months Ended September 30, 2012 | ||||||||||||||||||||
Personal Care | $ | 1 | $ | 30 | $ | — | $ | — | |||||||||||||||
Consumer Tissue | 7 | 22 | 31 | 80 | |||||||||||||||||||
K-C Professional | 3 | 12 | — | 5 | |||||||||||||||||||
Total | $ | 11 | $ | 64 | $ | 31 | $ | 85 | |||||||||||||||
Supplemental_Balance_Sheet_Dat
Supplemental Balance Sheet Data (Notes) | 9 Months Ended | ||||||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||||||
Statement of Financial Position [Abstract] | ' | ||||||||||||||||||||||||
Additional Financial Information Disclosure | ' | ||||||||||||||||||||||||
Supplemental Balance Sheet Data | |||||||||||||||||||||||||
The following schedule presents a summary of inventories by major class: | |||||||||||||||||||||||||
September 30, 2013 | December 31, 2012 | ||||||||||||||||||||||||
LIFO | Non-LIFO | Total | LIFO | Non-LIFO | Total | ||||||||||||||||||||
At the lower of cost, determined on the FIFO or weighted-average cost methods, or market | |||||||||||||||||||||||||
Raw materials | $ | 141 | $ | 329 | $ | 470 | $ | 148 | $ | 346 | $ | 494 | |||||||||||||
Work in process | 207 | 102 | 309 | 194 | 135 | 329 | |||||||||||||||||||
Finished goods | 634 | 743 | 1,377 | 656 | 786 | 1,442 | |||||||||||||||||||
Supplies and other | — | 329 | 329 | — | 314 | 314 | |||||||||||||||||||
982 | 1,503 | 2,485 | 998 | 1,581 | 2,579 | ||||||||||||||||||||
Excess of FIFO or weighted-average cost over LIFO cost | (240 | ) | — | (240 | ) | (231 | ) | — | (231 | ) | |||||||||||||||
Total | $ | 742 | $ | 1,503 | $ | 2,245 | $ | 767 | $ | 1,581 | $ | 2,348 | |||||||||||||
We use the LIFO method of valuing inventory for financial reporting purposes for most U.S. inventories. Interim LIFO calculations are based on management's estimates of expected year-end inventory levels and costs. An actual valuation of inventory under the LIFO method is made at the end of each year based on the inventory levels and costs at that time. | |||||||||||||||||||||||||
The following schedule presents a summary of property, plant and equipment, net: | |||||||||||||||||||||||||
September 30, 2013 | December 31, 2012 | ||||||||||||||||||||||||
Land | $ | 197 | $ | 199 | |||||||||||||||||||||
Buildings | 2,780 | 2,732 | |||||||||||||||||||||||
Machinery and equipment | 14,176 | 13,993 | |||||||||||||||||||||||
Construction in progress | 402 | 732 | |||||||||||||||||||||||
17,555 | 17,656 | ||||||||||||||||||||||||
Less accumulated depreciation | (9,684 | ) | (9,561 | ) | |||||||||||||||||||||
Total | $ | 7,871 | $ | 8,095 | |||||||||||||||||||||
Accounting_Policies_Accounting
Accounting Policies Accounting (Policies) | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Significant Accounting Policies | ' |
Accounting Policies | |
Basis of Presentation | |
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. | |
For further information, refer to the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2012. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries. | |
Annual Goodwill Impairment Test | |
Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. During the third quarter of 2013, we changed the measurement date of our annual goodwill impairment test from the beginning of the fourth quarter to the beginning of the third quarter. This change did not result in the delay, acceleration or avoidance of an impairment charge. We believe this timing is preferable as it better aligns the goodwill impairment test with our strategic business planning process, which is a key component of the goodwill impairment test. The change was applied prospectively, as retrospective application would have been impractical because we are unable to objectively select assumptions that would have been used in previous periods without the benefit of hindsight. We have completed the required annual testing of goodwill for impairment for all reporting units and have determined that goodwill is not impaired. | |
Highly Inflationary Accounting for Venezuelan Operations | |
We account for our operations in Venezuela using highly inflationary accounting. On February 13, 2013, the Venezuelan government announced a devaluation of the Central Bank of Venezuela ("Central Bank") regulated currency exchange system rate to 6.3 bolivars per U.S. dollar and the elimination of the SITME rate. As a result of the devaluation, we recorded a $26 after tax charge ($36 pre-tax) related to the remeasurement of the local currency-denominated balance sheet to the new exchange rate in the quarter ended March 31, 2013. Prior to devaluation, we used the Central Bank SITME rate of 5.4 bolivars per U.S. dollar to measure K-C Venezuela's bolivar-denominated transactions into U.S. dollars. The $36 pre-tax charge is reflected in the Consolidated Income Statement in other (income) and expense, net for the nine months ended September 30, 2013. In the Consolidated Cash Flow Statement, this non-cash charge is included in other in cash provided by operations. | |
At September 30, 2013, K-C Venezuela had a bolivar-denominated net monetary asset position of $285 and our net investment in K-C Venezuela was $414, both valued at 6.3 bolivars per U.S. dollar. Net sales of K-C Venezuela represented approximately 2 percent of consolidated net sales for the three and nine month periods ended September 30, 2013 and 2012. |
Fair_Value_Information_Policy
Fair Value Information (Policy) | 9 Months Ended |
Sep. 30, 2013 | |
Fair Value Disclosures [Abstract] | ' |
Fair Value Level Measurements Policy | ' |
The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are: | |
Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities. | |
Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly. | |
Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable. | |
A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. |
Supplemental_Balance_Sheet_Dat1
Supplemental Balance Sheet Data (Policies) | 9 Months Ended |
Sep. 30, 2013 | |
Statement of Financial Position [Abstract] | ' |
Inventory Policy | ' |
We use the LIFO method of valuing inventory for financial reporting purposes for most U.S. inventories. Interim LIFO calculations are based on management's estimates of expected year-end inventory levels and costs. An actual valuation of inventory under the LIFO method is made at the end of each year based on the inventory levels and costs at that time. |
European_Strategic_Changes_Tab
European Strategic Changes (Tables) (European Strategic Changes [Member]) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
European Strategic Changes [Member] | ' | |||||||
Restructuring Cost and Reserve | ' | |||||||
Charges Incurred in Connection with Restructuring | ' | |||||||
Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2013 | |||||||
Asset impairments | $ | 22 | $ | 22 | ||||
Charges for workforce reductions | (23 | ) | 4 | |||||
Asset write-offs | 1 | 13 | ||||||
Incremental depreciation | 3 | 18 | ||||||
Benefit from pension curtailment | (1 | ) | (30 | ) | ||||
Other exit costs | 4 | 17 | ||||||
Cost of products sold | 6 | 44 | ||||||
Charges for workforce reductions and other included in marketing, research and general expenses and other (income) and expense, net | 8 | 23 | ||||||
Provision for income taxes | (4 | ) | (15 | ) | ||||
Net charges | $ | 10 | $ | 52 | ||||
Schedule of Cash Charges Reconciled to Accrued Expenses | ' | |||||||
2013 | ||||||||
Accrued expenses - January 1 | $ | 133 | ||||||
Charges for workforce reductions and other costs | 53 | |||||||
Cash payments | (132 | ) | ||||||
Currency and other | (9 | ) | ||||||
Accrued expenses - September 30 | $ | 45 | ||||||
Fair_Value_Information_Tables
Fair Value Information (Tables) | 9 Months Ended | |||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||||||
Fair Value Assets And Liabilities Measured On A Recurring Basis | ' | |||||||||||||||||
Set forth below are the assets and liabilities that are measured on a recurring basis at fair value and the inputs used to develop those fair value measurements. | ||||||||||||||||||
September 30, 2013 | Fair Value Measurements | |||||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||||
Assets | ||||||||||||||||||
Company-owned life insurance (“COLI”) | $ | 53 | $ | — | $ | 53 | $ | — | ||||||||||
Available-for-sale securities | 20 | 20 | — | — | ||||||||||||||
Derivatives | 69 | — | 69 | — | ||||||||||||||
Total | $ | 142 | $ | 20 | $ | 122 | $ | — | ||||||||||
Liabilities | ||||||||||||||||||
Derivatives | $ | 57 | $ | — | $ | 57 | $ | — | ||||||||||
December 31, 2012 | Fair Value Measurements | |||||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||||
Assets | ||||||||||||||||||
COLI | $ | 49 | $ | — | $ | 49 | $ | — | ||||||||||
Available-for-sale securities | 17 | 17 | — | — | ||||||||||||||
Derivatives | 61 | — | 61 | — | ||||||||||||||
Total | $ | 127 | $ | 17 | $ | 110 | $ | — | ||||||||||
Liabilities | ||||||||||||||||||
Derivatives | $ | 63 | $ | — | $ | 63 | $ | — | ||||||||||
Fair Value, by Balance Sheet Grouping | ' | |||||||||||||||||
The following table includes the fair value of our financial instruments for which disclosure of fair value is required: | ||||||||||||||||||
Fair Value Hierarchy Level | Carrying Amount | Estimated Fair Value | Carrying Amount | Estimated Fair Value | ||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||||
Assets | ||||||||||||||||||
Cash and cash equivalents(a) | 1 | $ | 1,179 | $ | 1,179 | $ | 1,106 | $ | 1,106 | |||||||||
Time deposits(b) | 1 | 202 | 202 | 224 | 224 | |||||||||||||
Note receivable(c) | 3 | 396 | 397 | 395 | 392 | |||||||||||||
Liabilities and redeemable securities of subsidiaries | ||||||||||||||||||
Short-term debt(d) | 2 | 374 | 374 | 359 | 359 | |||||||||||||
Monetization loan(c) | 3 | 397 | 398 | 397 | 400 | |||||||||||||
Long-term debt(e) | 2 | 5,704 | 6,361 | 5,429 | 6,527 | |||||||||||||
Redeemable preferred securities of subsidiary(c) | 3 | 506 | 532 | 506 | 543 | |||||||||||||
Redeemable common securities of subsidiary(f) | 3 | 43 | 43 | 43 | 43 | |||||||||||||
(a) | Cash equivalents are comprised of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. | |||||||||||||||||
(b) | Time deposits are comprised of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value. | |||||||||||||||||
(c) | The note, monetization loan and redeemable preferred securities of subsidiary are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest payment dates. | |||||||||||||||||
(d) | Short-term debt is comprised of U.S. commercial paper and other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. | |||||||||||||||||
(e) | Long-term debt includes the current portion of these debt instruments and excludes the monetization loan. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly. | |||||||||||||||||
(f) | The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions. |
Employee_Postretirement_Benefi1
Employee Postretirement Benefits (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract] | ' | |||||||||||||||
Components of net periodic benefit cost | ' | |||||||||||||||
The table below presents net periodic benefit cost information for defined benefit plans and other postretirement benefit plans: | ||||||||||||||||
Pension Benefits | Other Benefits | |||||||||||||||
Three Months Ended September 30 | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Service cost | $ | 13 | $ | 10 | $ | 4 | $ | 3 | ||||||||
Interest cost | 63 | 69 | 9 | 9 | ||||||||||||
Expected return on plan assets | (82 | ) | (82 | ) | — | — | ||||||||||
Recognized net actuarial loss | 28 | 27 | 2 | — | ||||||||||||
Curtailment (see Note 2) | (1 | ) | — | — | — | |||||||||||
Other | 2 | 3 | — | 1 | ||||||||||||
Net periodic benefit cost | $ | 23 | $ | 27 | $ | 15 | $ | 13 | ||||||||
Pension Benefits | Other Benefits | |||||||||||||||
Nine Months Ended September 30 | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Service cost | $ | 40 | $ | 34 | $ | 12 | $ | 11 | ||||||||
Interest cost | 191 | 209 | 25 | 28 | ||||||||||||
Expected return on plan assets | (246 | ) | (247 | ) | — | — | ||||||||||
Recognized net actuarial loss | 91 | 82 | 2 | — | ||||||||||||
Curtailment (see Note 2) | (30 | ) | — | — | — | |||||||||||
Other | (1 | ) | 20 | — | — | |||||||||||
Net periodic benefit cost | $ | 45 | $ | 98 | $ | 39 | $ | 39 | ||||||||
Earnings_Per_Share_Tables
Earnings Per Share (Tables) | 9 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Earnings Per Share [Abstract] | ' | ||||||||||||
Average Common Shares Outstanding Basic and Diluted | ' | ||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||
30-Sep | 30-Sep | ||||||||||||
(Millions of shares) | 2013 | 2012 | 2013 | 2012 | |||||||||
Basic | 382.8 | 393.9 | 384.9 | 393.8 | |||||||||
Dilutive effect of stock options | 1.4 | 1.7 | 1.6 | 1.9 | |||||||||
Dilutive effect of restricted share and restricted share unit awards | 1.6 | 1.1 | 1.5 | 1.4 | |||||||||
Diluted | 385.8 | 396.7 | 388 | 397.1 | |||||||||
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Equity [Abstract] | ' | ||||||||||||||||
Components Of Stockholders' Equity | ' | ||||||||||||||||
Stockholders' Equity Attributable to | |||||||||||||||||
Comprehensive Income | The Corporation | Noncontrolling Interests | Redeemable Securities of Subsidiaries | ||||||||||||||
Balance at December 31, 2012 | $ | 4,985 | $ | 302 | $ | 549 | |||||||||||
Comprehensive Income | |||||||||||||||||
Net Income | $ | 1,663 | 1,603 | 37 | 23 | ||||||||||||
Other comprehensive income, net of tax | |||||||||||||||||
Unrealized translation | (387 | ) | (386 | ) | (1 | ) | — | ||||||||||
Employee postretirement benefits | 84 | 84 | — | — | |||||||||||||
Other | 9 | 9 | — | — | |||||||||||||
Total Comprehensive Income | $ | 1,369 | |||||||||||||||
Stock-based awards exercised or vested | 163 | — | — | ||||||||||||||
Recognition of stock-based compensation | 73 | — | — | ||||||||||||||
Income tax benefits on stock-based compensation | 30 | — | — | ||||||||||||||
Shares repurchased | (963 | ) | — | — | |||||||||||||
Dividends declared | (934 | ) | (27 | ) | — | ||||||||||||
Other | 3 | (1 | ) | (2 | ) | ||||||||||||
Return of redeemable securities of subsidiaries | — | (1 | ) | (21 | ) | ||||||||||||
Balance at September 30, 2013 | $ | 4,667 | $ | 309 | $ | 549 | |||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) | ' | ||||||||||||||||
Unrealized Translation | Defined Benefit Pension Plans | Other Postretirement Benefit Plans | Cash Flow Hedges and Other | ||||||||||||||
Balance as of December 31, 2011 | $ | (221 | ) | $ | (1,578 | ) | $ | (31 | ) | $ | (36 | ) | |||||
Other comprehensive income/(loss) before reclassifications | 124 | (101 | ) | (9 | ) | (10 | ) | ||||||||||
(Income)/loss reclassified from AOCI | — | 62 | (a) | — | (a) | — | |||||||||||
Net current period other comprehensive income/(loss) | 124 | (39 | ) | (9 | ) | (10 | ) | ||||||||||
Balance as of September 30, 2012 | $ | (97 | ) | $ | (1,617 | ) | $ | (40 | ) | $ | (46 | ) | |||||
Balance as of December 31, 2012 | $ | (26 | ) | $ | (1,928 | ) | $ | (53 | ) | $ | (52 | ) | |||||
Other comprehensive income/(loss) before reclassifications | (386 | ) | 57 | 1 | 17 | ||||||||||||
(Income)/loss reclassified from AOCI | — | 28 | (a) | (2 | ) | (a) | (8 | ) | |||||||||
Net current period other comprehensive income/(loss) | (386 | ) | 85 | (1 | ) | 9 | |||||||||||
Balance as of September 30, 2013 | $ | (412 | ) | $ | (1,843 | ) | $ | (54 | ) | $ | (43 | ) | |||||
(a) | Included in computation of net periodic pension and postretirement benefits costs (see Note 5). |
Objectives_And_Strategies_For_1
Objectives And Strategies For Using Derivatives (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | |||||||||||||||
Schedule Of Fair Value Of All Derivative Instruments | ' | |||||||||||||||
Assets | Liabilities | |||||||||||||||
September 30, | December 31, | September 30, | December 31, | |||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Foreign currency exchange contracts | $ | 52 | $ | 52 | $ | 55 | $ | 17 | ||||||||
Interest rate contracts | 16 | 7 | 1 | 43 | ||||||||||||
Commodity price contracts | 1 | 2 | 1 | 3 | ||||||||||||
Total | $ | 69 | $ | 61 | $ | 57 | $ | 63 | ||||||||
Description_Of_Business_Segmen1
Description Of Business Segments (Tables) | 9 Months Ended | ||||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||||
Description of Business Segments | ' | ||||||||||||||||||||||
Information Concerning Consolidated Operations by Business Segment | ' | ||||||||||||||||||||||
Three Months Ended September 30 | Nine Months Ended September 30 | ||||||||||||||||||||||
2013 | 2012 | Change | 2013 | 2012 | Change | ||||||||||||||||||
NET SALES | |||||||||||||||||||||||
Personal Care | $ | 2,383 | $ | 2,414 | -1.3 | % | $ | 7,170 | $ | 7,196 | -0.4 | % | |||||||||||
Consumer Tissue | 1,626 | 1,605 | 1.3 | % | 4,969 | 4,852 | 2.4 | % | |||||||||||||||
K-C Professional | 843 | 822 | 2.6 | % | 2,477 | 2,458 | 0.8 | % | |||||||||||||||
Health Care | 403 | 396 | 1.8 | % | 1,201 | 1,212 | -0.9 | % | |||||||||||||||
Corporate & Other | 7 | 9 | N.M. | 30 | 38 | N.M. | |||||||||||||||||
TOTAL NET SALES | $ | 5,262 | $ | 5,246 | 0.3 | % | $ | 15,847 | $ | 15,756 | 0.6 | % | |||||||||||
OPERATING PROFIT | |||||||||||||||||||||||
Personal Care | $ | 427 | $ | 436 | -2.1 | % | $ | 1,300 | $ | 1,241 | 4.8 | % | |||||||||||
Consumer Tissue | 233 | 216 | 7.9 | % | 713 | 652 | 9.4 | % | |||||||||||||||
K-C Professional | 155 | 144 | 7.6 | % | 459 | 407 | 12.8 | % | |||||||||||||||
Health Care | 70 | 59 | 18.6 | % | 168 | 168 | — | ||||||||||||||||
Corporate & Other(a) | (70 | ) | (77 | ) | N.M. | (242 | ) | (246 | ) | N.M. | |||||||||||||
Other (income) and expense, net | 8 | (5 | ) | N.M. | 12 | (15 | ) | N.M. | |||||||||||||||
TOTAL OPERATING PROFIT | $ | 807 | $ | 783 | 3.1 | % | $ | 2,386 | $ | 2,237 | 6.7 | % | |||||||||||
N.M. - Not meaningful | |||||||||||||||||||||||
(a) | Corporate & Other includes the following charges: | ||||||||||||||||||||||
European Strategic Changes | Pulp & Tissue Restructuring Actions | ||||||||||||||||||||||
Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2013 | Three Months Ended September 30, 2012 | Nine Months Ended September 30, 2012 | ||||||||||||||||||||
Personal Care | $ | 1 | $ | 30 | $ | — | $ | — | |||||||||||||||
Consumer Tissue | 7 | 22 | 31 | 80 | |||||||||||||||||||
K-C Professional | 3 | 12 | — | 5 | |||||||||||||||||||
Total | $ | 11 | $ | 64 | $ | 31 | $ | 85 | |||||||||||||||
Summary_of_Balance_Sheet_Data_
Summary of Balance Sheet Data (Tables) | 9 Months Ended | ||||||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||||||
Statement of Financial Position [Abstract] | ' | ||||||||||||||||||||||||
Schedule of Inventory, Current | ' | ||||||||||||||||||||||||
September 30, 2013 | December 31, 2012 | ||||||||||||||||||||||||
LIFO | Non-LIFO | Total | LIFO | Non-LIFO | Total | ||||||||||||||||||||
At the lower of cost, determined on the FIFO or weighted-average cost methods, or market | |||||||||||||||||||||||||
Raw materials | $ | 141 | $ | 329 | $ | 470 | $ | 148 | $ | 346 | $ | 494 | |||||||||||||
Work in process | 207 | 102 | 309 | 194 | 135 | 329 | |||||||||||||||||||
Finished goods | 634 | 743 | 1,377 | 656 | 786 | 1,442 | |||||||||||||||||||
Supplies and other | — | 329 | 329 | — | 314 | 314 | |||||||||||||||||||
982 | 1,503 | 2,485 | 998 | 1,581 | 2,579 | ||||||||||||||||||||
Excess of FIFO or weighted-average cost over LIFO cost | (240 | ) | — | (240 | ) | (231 | ) | — | (231 | ) | |||||||||||||||
Total | $ | 742 | $ | 1,503 | $ | 2,245 | $ | 767 | $ | 1,581 | $ | 2,348 | |||||||||||||
Property, Plant and Equipment | ' | ||||||||||||||||||||||||
September 30, 2013 | December 31, 2012 | ||||||||||||||||||||||||
Land | $ | 197 | $ | 199 | |||||||||||||||||||||
Buildings | 2,780 | 2,732 | |||||||||||||||||||||||
Machinery and equipment | 14,176 | 13,993 | |||||||||||||||||||||||
Construction in progress | 402 | 732 | |||||||||||||||||||||||
17,555 | 17,656 | ||||||||||||||||||||||||
Less accumulated depreciation | (9,684 | ) | (9,561 | ) | |||||||||||||||||||||
Total | $ | 7,871 | $ | 8,095 | |||||||||||||||||||||
Accounting_Policies_Narrative_
Accounting Policies Narrative (Details) (K-C Venezuela [Member], USD $) | 3 Months Ended | 9 Months Ended | 33 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Feb. 01, 2013 |
K-C Venezuela [Member] | ' | ' | ' | ' | ' |
Central Bank System Rate | ' | ' | 6.3 | ' | 5.4 |
Charge for Devaluation Under Highly Inflationary Accounting (after tax) | ' | ' | $26 | ' | ' |
Charge for Devaluation Under Highly Inflationary Accounting | ' | ' | 36 | ' | ' |
Bolivar Denominated Monetary Asset Net | 285 | ' | 285 | ' | ' |
Net Investment Foreign Operations | $414 | ' | $414 | ' | ' |
Portion Of Consolidate Net Sales Earned By Affiliate Percent | 2.00% | 2.00% | 2.00% | 2.00% | ' |
European_Strategic_Changes_Nar
European Strategic Changes - Narrative (Details) (European Strategic Changes [Member], USD $) | 3 Months Ended | 9 Months Ended | 11 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | ||
Restructuring Cost and Reserve | ' | ' | ' | ||
Restructuring Activities for Manufacturing Facilities | ' | 5 | ' | ||
Charges for workforce reductions and other costs | ' | ' | $366 | ||
Restructuring Charges After Tax | 10 | 52 | 294 | ||
Personal Care [Member] | ' | ' | ' | ||
Restructuring Cost and Reserve | ' | ' | ' | ||
Charges for workforce reductions and other costs | 1 | [1] | 30 | [1] | 243 |
Consumer Tissue [Member] | ' | ' | ' | ||
Restructuring Cost and Reserve | ' | ' | ' | ||
Charges for workforce reductions and other costs | 7 | [1] | 22 | [1] | 88 |
K-C Professional | ' | ' | ' | ||
Restructuring Cost and Reserve | ' | ' | ' | ||
Charges for workforce reductions and other costs | 3 | [1] | 12 | [1] | 32 |
Cash charges [Member] | ' | ' | ' | ||
Restructuring Cost and Reserve | ' | ' | ' | ||
Charges for workforce reductions and other costs | ' | $53 | $187 | ||
[1] | Corporate & Other includes the following charges: |
European_Strategic_Changes_Cha
European Strategic Changes - Charges Incurred (Details) (European Strategic Changes [Member], USD $) | 3 Months Ended | 9 Months Ended | 11 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | ' | ' | $366 |
Restructuring Charges After Tax | 10 | 52 | 294 |
Cost of Sales [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | 6 | 44 | ' |
Charges for workforce reductions and other included in marketing, research and general and other (income) and expense, net [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | 8 | 23 | ' |
Provision for income taxes | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | -4 | -15 | ' |
Asset Impairments [Member] | Cost of Sales [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | 22 | 22 | ' |
Employee Severance [Member] | Cost of Sales [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | -23 | 4 | ' |
Asset write-offs | Cost of Sales [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | 1 | 13 | ' |
Incremental depreciation | Cost of Sales [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | 3 | 18 | ' |
Benefit from pension curtailment | Cost of Sales [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | -1 | -30 | ' |
Other exit costs | Cost of Sales [Member] | ' | ' | ' |
Restructuring Cost and Reserve | ' | ' | ' |
Charges for workforce reductions and other costs | $4 | $17 | ' |
European_Strategic_Changes_Rec
European Strategic Changes - Reconciliation to Accrued Expenses (Details) (European Strategic Changes [Member], USD $) | 9 Months Ended | 11 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2013 |
Accrued Expense Roll Forward | ' | ' |
Accrued expenses - January 1 | $133 | ' |
Charges for workforce reductions and other costs | ' | 366 |
Cash payments | -132 | ' |
Currency and other | -9 | ' |
Accrued expenses - September 30 | 45 | 45 |
Cash charges [Member] | ' | ' |
Accrued Expense Roll Forward | ' | ' |
Charges for workforce reductions and other costs | $53 | $187 |
Pulp_And_Tissue_Restructuring_
Pulp And Tissue Restructuring (Narrative) (Details) (Pulp And Tissue Restructuring [Member], USD $) | 3 Months Ended | 9 Months Ended | |
In Millions, unless otherwise specified | Sep. 30, 2012 | Sep. 30, 2012 | |
Restructuring Cost and Reserve [Line Items] | ' | ' | |
Restructuring Activities for Manufacturing Facilities | ' | 7 | |
Charges for workforce reductions and other costs | ($31) | [1] | ($85) |
UNITED STATES | ' | ' | |
Restructuring Cost and Reserve [Line Items] | ' | ' | |
Charges for workforce reductions and other costs | -10 | -58 | |
AUSTRALIA | ' | ' | |
Restructuring Cost and Reserve [Line Items] | ' | ' | |
Charges for workforce reductions and other costs | -22 | -27 | |
Other Geographic Areas [Member] | ' | ' | |
Restructuring Cost and Reserve [Line Items] | ' | ' | |
Charges for workforce reductions and other costs | -1 | ' | |
Cost of Sales [Member] | ' | ' | |
Restructuring Cost and Reserve [Line Items] | ' | ' | |
Charges for workforce reductions and other costs | -30 | -83 | |
Charges for workforce reductions and other included in marketing, research and general expenses | ' | ' | |
Restructuring Cost and Reserve [Line Items] | ' | ' | |
Charges for workforce reductions and other costs | -1 | -2 | |
Provision for income taxes | ' | ' | |
Restructuring Cost and Reserve [Line Items] | ' | ' | |
Charges for workforce reductions and other costs | $15 | $29 | |
[1] | Corporate & Other includes the following charges: |
Fair_Value_Information_Narrati
Fair Value Information (Narrative) (Details) (USD $) | 9 Months Ended | 12 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 | Dec. 31, 2012 |
Fair Value Disclosures [Abstract] | ' | ' |
Transfers among fair value determination | $0 | $0 |
Fair_Value_Information_Fair_Va
Fair Value Information (Fair Value Assets And Liabilities Measured On A Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ' | ' |
Company-owned life insurance (bCOLIb) | $53 | $49 |
Available-for-sale securities | 20 | 17 |
Derivatives | 69 | 61 |
Total | 142 | 127 |
Derivatives | 57 | 63 |
Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ' | ' |
Company-owned life insurance (bCOLIb) | 0 | 0 |
Available-for-sale securities | 20 | 17 |
Derivatives | 0 | 0 |
Total | 20 | 17 |
Derivatives | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ' | ' |
Company-owned life insurance (bCOLIb) | 53 | 49 |
Available-for-sale securities | 0 | 0 |
Derivatives | 69 | 61 |
Total | 122 | 110 |
Derivatives | 57 | 63 |
Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ' | ' |
Company-owned life insurance (bCOLIb) | 0 | 0 |
Available-for-sale securities | 0 | 0 |
Derivatives | 0 | 0 |
Total | 0 | 0 |
Derivatives | $0 | $0 |
Fair_Value_Information_Fair_Va1
Fair Value Information (Fair Value Of Financial Instruments) (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | ||
In Millions, unless otherwise specified | ||||
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Cash and cash equivalents(a) | $1,179 | [1] | $1,106 | [1] |
Time deposits(b) | 202 | [2] | 224 | [2] |
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Short-term debt(d) | 374 | [3] | 359 | [3] |
Long-term debt(e) | 5,704 | [4] | 5,429 | [4] |
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Note receivable(c) | 396 | [5] | 395 | [5] |
Monetization loan(c) | 397 | [5] | 397 | [5] |
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Cash and cash equivalents(a) | 1,179 | [1] | 1,106 | [1] |
Time deposits(b) | 202 | [2] | 224 | [2] |
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Short-term debt(d) | 374 | [3] | 359 | [3] |
Long-term debt(e) | 6,361 | [4] | 6,527 | [4] |
Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Note receivable(c) | 397 | [5] | 392 | [5] |
Monetization loan(c) | 398 | [5] | 400 | [5] |
Preferred securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Redeemable preferred securities of subsidiary(c) | 506 | [5] | 506 | [5] |
Preferred securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Redeemable preferred securities of subsidiary(c) | 532 | [5] | 543 | [5] |
common securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Redeemable preferred securities of subsidiary(c) | 43 | [6] | 43 | [6] |
common securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions | ' | ' | ||
Redeemable preferred securities of subsidiary(c) | $43 | [6] | $43 | [6] |
[1] | Cash equivalents are comprised of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value. | |||
[2] | Time deposits are comprised of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in other current assets or other assets in the Consolidated Balance Sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value. | |||
[3] | Short-term debt is comprised of U.S. commercial paper and other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value. | |||
[4] | Long-term debt includes the current portion of these debt instruments and excludes the monetization loan. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly. | |||
[5] | The note, monetization loan and redeemable preferred securities of subsidiary are not traded in active markets. Accordingly, their fair values were calculated using a floating rate pricing model that compared the stated spread to the fair value spread to determine the price at which each of the financial instruments should trade. The model used the following inputs to calculate fair values: face value, current LIBOR rate, unobservable fair value credit spread, stated spread, maturity date and interest payment dates. | |||
[6] | The fair value of the redeemable common securities of subsidiary was based on various inputs, including an independent third-party appraisal, adjusted for current market conditions. |
Employee_Postretirement_Benefi2
Employee Postretirement Benefits (Narrative) (Details) (USD $) | 9 Months Ended | |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract] | ' | ' |
Cash contribution to pension trusts | $175 | $95 |
Defined Benefit Plan, Estimated Future Employer Contributions in Current Fiscal Year | $200 | ' |
Employee_Postretirement_Benefi3
Employee Postretirement Benefits (Benefit Cost Information For Defined Benefit Plans And Other Postretirement Benefit Plans) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Defined Benefit Plans [Member] | ' | ' | ' | ' |
Defined Benefit Plans and Other Postretirement Benefit Plans | ' | ' | ' | ' |
Service cost | $13 | $10 | $40 | $34 |
Interest cost | 63 | 69 | 191 | 209 |
Expected return on plan assets | -82 | -82 | -246 | -247 |
Recognized net actuarial loss | 28 | 27 | 91 | 82 |
Curtailment (see Note 2) | -1 | 0 | -30 | 0 |
Other | 2 | 3 | -1 | 20 |
Net periodic benefit cost | 23 | 27 | 45 | 98 |
Other Postretirement Benefit Plans [Member] | ' | ' | ' | ' |
Defined Benefit Plans and Other Postretirement Benefit Plans | ' | ' | ' | ' |
Service cost | 4 | 3 | 12 | 11 |
Interest cost | 9 | 9 | 25 | 28 |
Expected return on plan assets | 0 | 0 | 0 | 0 |
Recognized net actuarial loss | 2 | 0 | 2 | 0 |
Curtailment (see Note 2) | 0 | 0 | 0 | 0 |
Other | 0 | 1 | 0 | 0 |
Net periodic benefit cost | $15 | $13 | $39 | $39 |
Earnings_Per_Share_Narrative_D
Earnings Per Share (Narrative) (Details) | 3 Months Ended | 9 Months Ended | |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 |
Earnings Per Share [Abstract] | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1.8 | 0.9 | ' |
Common shares outstanding | 382.1 | 382.1 | 392.3 |
Earnings_Per_Share_Average_Com
Earnings Per Share (Average Common Shares Outstanding Basic And Diluted) (Details) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Earnings Per Share [Abstract] | ' | ' | ' | ' |
Basic | 382.8 | 393.9 | 384.9 | 393.8 |
Dilutive effect of stock options | 1.4 | 1.7 | 1.6 | 1.9 |
Dilutive effect of restricted share and restricted share unit awards | 1.6 | 1.1 | 1.5 | 1.4 |
Diluted | 385.8 | 396.7 | 388 | 397.1 |
Stockholders_Equity_Narrative_
Stockholders' Equity (Narrative) (Details) (USD $) | 9 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 |
Equity [Abstract] | ' |
Repurchased shares | 10 |
Stock Repurchased During Period, Value | $950 |
Stockholders_Equity_Components
Stockholders' Equity (Components Of Stockholders' Equity) (Details) (USD $) | 3 Months Ended | 9 Months Ended | |||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 |
Redeemable Preferred and Common Securities of Subsidiaries | $549 | ' | $549 | ' | $549 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' |
Balance at December 31, 2012 | ' | ' | 5,287 | ' | ' |
Net Income | 565 | 537 | 1,663 | 1,542 | ' |
Temporary Equity, Net Income | ' | ' | 23 | ' | ' |
Unrealized currency translation adjustments | 204 | 141 | -387 | 133 | ' |
Employee postretirement benefits | -5 | -54 | 84 | -46 | ' |
Other | -19 | -10 | 9 | -10 | ' |
Comprehensive Income | 745 | 614 | 1,369 | 1,619 | ' |
Recognition of stock-based compensation | ' | ' | -73 | -57 | ' |
Balance at September 30, 2013 | 4,976 | ' | 4,976 | ' | ' |
Parent [Member] | ' | ' | ' | ' | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' |
Balance at December 31, 2012 | ' | ' | 4,985 | ' | ' |
Net Income | ' | ' | 1,603 | ' | ' |
Unrealized currency translation adjustments | ' | ' | -386 | 124 | ' |
Employee postretirement benefits | ' | ' | 84 | ' | ' |
Other | ' | ' | 9 | -10 | ' |
Stock-based awards exercised or vested | ' | ' | 163 | ' | ' |
Recognition of stock-based compensation | ' | ' | 73 | ' | ' |
Income tax benefits on stock-based compensation | ' | ' | 30 | ' | ' |
Shares repurchased | ' | ' | -963 | ' | ' |
Dividends declared | ' | ' | -934 | ' | ' |
Other | ' | ' | 3 | ' | ' |
Temporary Equity, Return | ' | ' | 0 | ' | ' |
Balance at September 30, 2013 | 4,667 | ' | 4,667 | ' | ' |
Noncontrolling Interests [Member] | ' | ' | ' | ' | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' |
Balance at December 31, 2012 | ' | ' | 302 | ' | ' |
Net Income | ' | ' | 37 | ' | ' |
Unrealized currency translation adjustments | ' | ' | -1 | ' | ' |
Employee postretirement benefits | ' | ' | 0 | ' | ' |
Other | ' | ' | 0 | ' | ' |
Stock-based awards exercised or vested | ' | ' | 0 | ' | ' |
Recognition of stock-based compensation | ' | ' | 0 | ' | ' |
Income tax benefits on stock-based compensation | ' | ' | 0 | ' | ' |
Shares repurchased | ' | ' | 0 | ' | ' |
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders | ' | ' | -27 | ' | ' |
Other | ' | ' | -1 | ' | ' |
Temporary Equity, Return | ' | ' | -1 | ' | ' |
Balance at September 30, 2013 | 309 | ' | 309 | ' | ' |
Redeemable Securities Of Subsidiaries [Member] | ' | ' | ' | ' | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' |
Temporary Equity, Other Changes | ' | ' | -2 | ' | ' |
Temporary Equity, Return | ' | ' | ($21) | ' | ' |
Stockholders_Equity_Components1
Stockholders' Equity (Components of Accumulated Other Comprehensive Income) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Unrealized translation - Beginning balance | ' | ' | ($26) | ($221) |
Cash flow hedge and other - Beginning balance | ' | ' | -52 | -36 |
Other comprehensive income/(loss) before reclassifications | ' | ' | -386 | 124 |
(Income)/loss reclassified from AOCI | ' | ' | 0 | 0 |
Other comprehensive income/(loss) before reclassifications | ' | ' | 17 | -10 |
Income/loss reclassified from AOCI | ' | ' | -8 | 0 |
Unrealized currency translation adjustments | 204 | 141 | -387 | 133 |
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax | 5 | 54 | -84 | 46 |
Unrealized translation - Ending balance | -412 | -97 | -412 | -97 |
Cash flow hedge and other - Ending balance | -43 | -46 | -43 | -46 |
Other | -19 | -10 | 9 | -10 |
Pension Plans, Defined Benefit [Member] | ' | ' | ' | ' |
Defined benefit and other postretirement benefit plans - Beginning balance | ' | ' | -1,928 | -1,578 |
Other comprehensive income/(loss) before reclassifications | ' | ' | 57 | -101 |
(Income)/loss reclassified from AOCI | ' | ' | 28 | 62 |
Defined benefit and other postretirement benefit plans - Ending balance | -1,843 | -1,617 | -1,843 | -1,617 |
Other Postretirement Benefit Plans, Defined Benefit [Member] | ' | ' | ' | ' |
Defined benefit and other postretirement benefit plans - Beginning balance | ' | ' | -53 | -31 |
Other comprehensive income/(loss) before reclassifications | ' | ' | 1 | -9 |
(Income)/loss reclassified from AOCI | ' | ' | -2 | 0 |
Defined benefit and other postretirement benefit plans - Ending balance | -54 | -40 | -54 | -40 |
Parent [Member] | ' | ' | ' | ' |
Unrealized currency translation adjustments | ' | ' | -386 | 124 |
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax | ' | ' | -84 | ' |
Other | ' | ' | 9 | -10 |
Parent [Member] | Pension Plans, Defined Benefit [Member] | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax | ' | ' | -85 | 39 |
Parent [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax | ' | ' | $1 | $9 |
Objectives_And_Strategies_For_2
Objectives And Strategies For Using Derivatives (Narratives) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ' | ' | ' |
Notional Amount of Derivative Instruments Designated as Net Investment Hedges | $73,000,000 | ' | $73,000,000 | ' |
Interest rate swap contracts designated as fair value hedge | 250,000,000 | ' | 250,000,000 | ' |
Fair Value Hedge Ineffectiveness is Immaterial Assertion | ' | ' | 'Fair value hedges resulted in no significant ineffectiveness in the nine months ended September 30, 2013 and 2012 | ' |
Gains or losses recognized in Other (income) and expense for foreign exchange contracts, and Interest expense for interest rates swaps were not significant | ' | ' | 'For the nine month periods ended SeptemberB 30, 2013 and 2012, gains or losses recognized in interest expense for interest rate swaps were not significant. | ' |
Gain from Hedged Firm Commitment Not Qualifying as Fair Value Hedge | ' | ' | 0 | 0 |
Notional value of derivative contracts designated as cash flow hedges | 1,000,000,000 | ' | 1,000,000,000 | ' |
Interest rate swap contracts designated as cash flow hedge | 200,000,000 | ' | 200,000,000 | ' |
Cash Flow Hedge Ineffectiveness is Immaterial | ' | ' | 'Cash flow hedges resulted in no significant ineffectiveness for the nine months ended September 30, 2013 and 2012 | ' |
Gain (Loss) on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net | ' | ' | 0 | 0 |
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments | 77,000,000 | 30,000,000 | -65,000,000 | 31,000,000 |
Notional Amount of Foreign Currency Derivatives Intercompany | $2,600,000,000 | ' | $2,600,000,000 | ' |
Objectives_And_Strategies_For_3
Objectives And Strategies For Using Derivatives Summary of total and undesignated fair values of derivative instruments (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Derivative | ' | ' |
Assets | $69 | $61 |
Liabilities | 57 | 63 |
Foreign currency exchange contracts | ' | ' |
Derivative | ' | ' |
Assets | 52 | 52 |
Liabilities | 55 | 17 |
Interest rate contracts | ' | ' |
Derivative | ' | ' |
Assets | 16 | 7 |
Liabilities | 1 | 43 |
Commodity price contracts | ' | ' |
Derivative | ' | ' |
Assets | 1 | 2 |
Liabilities | $1 | $3 |
Description_Of_Business_Segmen2
Description Of Business Segments (Details) (USD $) | 3 Months Ended | 9 Months Ended | 11 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 11 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 11 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 11 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||||||||||||||||||||||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |||||||||||||||||
European Strategic Changes [Member] | Pulp And Tissue Restructuring [Member] | Pulp And Tissue Restructuring [Member] | Cost of products sold and marketing, research and general expenses [Member] | Cost of products sold and marketing, research and general expenses [Member] | Net Sales [Member] | Net Sales [Member] | Operating Profit [Member] | Operating Profit [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Personal Care [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | Consumer Tissue [Member] | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | K-C Professional | Health Care [Member] | Health Care [Member] | Health Care [Member] | Health Care [Member] | Health Care [Member] | Health Care [Member] | Health Care [Member] | Health Care [Member] | Corporate and Other [Member] | Corporate and Other [Member] | Corporate and Other [Member] | Corporate and Other [Member] | ||||||||||||||||||||||
European Strategic Changes [Member] | European Strategic Changes [Member] | European Strategic Changes [Member] | European Strategic Changes [Member] | European Strategic Changes [Member] | Pulp And Tissue Restructuring [Member] | Pulp And Tissue Restructuring [Member] | Net Sales [Member] | Net Sales [Member] | Operating Profit [Member] | Operating Profit [Member] | European Strategic Changes [Member] | European Strategic Changes [Member] | European Strategic Changes [Member] | Pulp And Tissue Restructuring [Member] | Pulp And Tissue Restructuring [Member] | Net Sales [Member] | Net Sales [Member] | Operating Profit [Member] | Operating Profit [Member] | European Strategic Changes [Member] | European Strategic Changes [Member] | European Strategic Changes [Member] | Pulp And Tissue Restructuring [Member] | Pulp And Tissue Restructuring [Member] | Net Sales [Member] | Net Sales [Member] | Operating Profit [Member] | Operating Profit [Member] | Net Sales [Member] | Net Sales [Member] | Operating Profit [Member] | Operating Profit [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Consolidated Net Sales | $5,262 | $5,246 | $15,847 | $15,756 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2,383 | $2,414 | $7,170 | $7,196 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,626 | $1,605 | $4,969 | $4,852 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $843 | $822 | $2,477 | $2,458 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $403 | $396 | $1,201 | $1,212 | ' | ' | ' | ' | $7 | $9 | $30 | $38 | |||||||||||||||||
Percent change | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.30% | 0.58% | 3.07% | 6.66% | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1.28% | -0.36% | -2.06% | 4.75% | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.31% | 2.41% | 7.87% | 9.36% | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.55% | 0.77% | 7.64% | 12.78% | ' | ' | ' | ' | 1.77% | -0.91% | 18.64% | 0.00% | ' | ' | ' | ' | |||||||||||||||||
Total Operating Profit | 807 | 783 | 2,386 | 2,237 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 427 | 436 | 1,300 | 1,241 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 233 | 216 | 713 | 652 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 155 | 144 | 459 | 407 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 70 | 59 | 168 | 168 | ' | ' | ' | ' | -70 | [1] | -77 | [1] | -242 | [1] | -246 | [1] | |||||||||||||
Other (income) and expense, net | 8 | -5 | 12 | -15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||||||||||||||
Restructuring charges, before tax | ' | ' | ' | ' | $366 | $31 | [1] | $85 | $11 | [1] | $64 | [1] | ' | ' | ' | ' | ' | ' | ' | ' | $1 | [1] | $30 | [1] | $243 | $0 | [1] | $0 | ' | ' | ' | ' | ' | ' | ' | ' | $7 | [1] | $22 | [1] | $88 | $31 | [1] | $80 | [1] | ' | ' | ' | ' | ' | ' | ' | ' | $3 | [1] | $12 | [1] | $32 | $0 | [1] | $5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
[1] | Corporate & Other includes the following charges: |
Supplemental_Balance_Sheet_Dat2
Supplemental Balance Sheet Data - Inventory (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Raw materials | $470 | $494 |
Work in process | 309 | 329 |
Finished goods | 1,377 | 1,442 |
Supplies and other | 329 | 314 |
Inventory, Gross | 2,485 | 2,579 |
Excess of FIFO or weighted-average cost over LIFO cost | -240 | -231 |
Total | 2,245 | 2,348 |
LIFO [Member] | ' | ' |
Raw materials | 141 | 148 |
Work in process | 207 | 194 |
Finished goods | 634 | 656 |
Supplies and other | 0 | 0 |
Inventory, Gross | 982 | 998 |
Excess of FIFO or weighted-average cost over LIFO cost | -240 | -231 |
Total | 742 | 767 |
Non-LIFO [Member] | ' | ' |
Raw materials | 329 | 346 |
Work in process | 102 | 135 |
Finished goods | 743 | 786 |
Supplies and other | 329 | 314 |
Inventory, Gross | 1,503 | 1,581 |
Excess of FIFO or weighted-average cost over LIFO cost | 0 | 0 |
Total | $1,503 | $1,581 |
Supplemental_Balance_Sheet_Dat3
Supplemental Balance Sheet Data - Property Plant and Equipment (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | $17,555 | $17,656 |
Less accumulated depreciation | -9,684 | -9,561 |
Total | 7,871 | 8,095 |
Land [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 197 | 199 |
Building [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 2,780 | 2,732 |
Machinery and Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 14,176 | 13,993 |
Construction in Progress [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | $402 | $732 |